SI2758432T1 - Nevtralizirajoča protitelesa proti glavnim eksotoksinom TCDA in TCDB iz clostridium difficile - Google Patents

Nevtralizirajoča protitelesa proti glavnim eksotoksinom TCDA in TCDB iz clostridium difficile

Info

Publication number
SI2758432T1
SI2758432T1 SI201231613T SI201231613T SI2758432T1 SI 2758432 T1 SI2758432 T1 SI 2758432T1 SI 201231613 T SI201231613 T SI 201231613T SI 201231613 T SI201231613 T SI 201231613T SI 2758432 T1 SI2758432 T1 SI 2758432T1
Authority
SI
Slovenia
Prior art keywords
tcdb
clostridium difficile
neutralising antibodies
tcda
major
Prior art date
Application number
SI201231613T
Other languages
English (en)
Inventor
David Paul Humphreys
Daniel John Lightwood
Kerry Louise Tyson
David Edward Ormonde Knight
Karine Jeannine Madeleine Herve
Joanne Elizabeth Compson
Matthew Jon Timothy Page
Andrew Charles Payne
Nicola Louise Fisher
Brendon Mackenzie
Matthew Cox
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46881094&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2758432(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of SI2758432T1 publication Critical patent/SI2758432T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91091—Glycosyltransferases (2.4)
    • G01N2333/91097—Hexosyltransferases (general) (2.4.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SI201231613T 2011-09-16 2012-09-10 Nevtralizirajoča protitelesa proti glavnim eksotoksinom TCDA in TCDB iz clostridium difficile SI2758432T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161535532P 2011-09-16 2011-09-16
US201261638731P 2012-04-26 2012-04-26
EP12761789.2A EP2758432B1 (en) 2011-09-16 2012-09-10 Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile
PCT/GB2012/052222 WO2013038156A1 (en) 2011-09-16 2012-09-10 Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile

Publications (1)

Publication Number Publication Date
SI2758432T1 true SI2758432T1 (sl) 2019-07-31

Family

ID=46881094

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201231613T SI2758432T1 (sl) 2011-09-16 2012-09-10 Nevtralizirajoča protitelesa proti glavnim eksotoksinom TCDA in TCDB iz clostridium difficile

Country Status (29)

Country Link
US (2) US10752676B2 (sl)
EP (2) EP3617227A3 (sl)
JP (3) JP6152107B2 (sl)
KR (1) KR20140063825A (sl)
CN (2) CN103958544B (sl)
AU (1) AU2012307157B2 (sl)
BR (1) BR112014006175B1 (sl)
CA (1) CA2848611A1 (sl)
CL (1) CL2014000491A1 (sl)
CO (1) CO6930310A2 (sl)
CY (1) CY1121673T1 (sl)
DK (1) DK2758432T3 (sl)
EA (1) EA032475B1 (sl)
EC (1) ECSP14013316A (sl)
ES (1) ES2729278T3 (sl)
HK (1) HK1199463A1 (sl)
HR (1) HRP20190917T1 (sl)
HU (1) HUE043661T2 (sl)
IL (1) IL231167A0 (sl)
LT (1) LT2758432T (sl)
MX (1) MX2014002769A (sl)
PE (1) PE20141547A1 (sl)
PL (1) PL2758432T3 (sl)
PT (1) PT2758432T (sl)
SG (2) SG11201400193SA (sl)
SI (1) SI2758432T1 (sl)
TN (1) TN2014000101A1 (sl)
WO (1) WO2013038156A1 (sl)
ZA (1) ZA201402760B (sl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140063825A (ko) * 2011-09-16 2014-05-27 유씨비 파마, 에스.에이. 클로스트리듐 디피실의 주요 외독소 tcda 및 tcdb에 대한 중화 항체
CA2892973A1 (en) * 2012-11-28 2014-06-05 Cnj Holdings, Inc. Antibodies against clostridium difficile
CN105451762A (zh) * 2013-04-22 2016-03-30 俄克拉荷马州大学评议会 艰难梭菌疫苗及使用方法
CA2939969A1 (en) 2014-02-18 2015-08-27 The Hospital For Sick Children Compositions and methods for treating or preventing clostridium infection
US9717711B2 (en) 2014-06-16 2017-08-01 The Lauridsen Group Methods and compositions for treating Clostridium difficile associated disease
WO2016178773A1 (en) * 2015-04-06 2016-11-10 Saureus, Inc. System and method for detecting clostridium difficile toxins
WO2016168392A1 (en) * 2015-04-15 2016-10-20 Medimmune, Llc Methods for treating clostridium difficile infection and associated disease
US10709758B2 (en) 2015-09-03 2020-07-14 The Board Of Regents Of The University Of Oklahoma Peptide inhibitors of clostridium difficile toxin B (TcdB) toxin
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
PE20231655A1 (es) 2015-10-02 2023-10-17 Hoffmann La Roche Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso
USD864160S1 (en) 2016-12-06 2019-10-22 Samsung Electronics Co., Ltd. Audio device
CN110607314B (zh) * 2019-10-31 2022-09-23 四川农业大学 一种TcdB RBD基因、重组RBD蛋白和应用
CN111763263A (zh) * 2020-07-09 2020-10-13 宁夏医科大学 一种艰难梭菌抗原及多克隆抗体的制备方法和检测试剂盒
CN112500484B (zh) * 2021-01-29 2021-06-08 迈杰转化医学研究(苏州)有限公司 一种抗trop2抗体及其应用

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
WO1992002551A1 (en) 1990-08-02 1992-02-20 B.R. Centre Limited Methods for the production of proteins with a desired function
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9113120D0 (en) 1991-06-18 1991-08-07 Kodak Ltd Photographic processing apparatus
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
CA2085827C (en) 1991-12-23 2003-10-14 Lucas A. T. Hilgers Adjuvant composition containing synthetic hydrophobic lipopolysaccharide
DE69327599T2 (de) 1992-06-25 2000-08-10 Smithkline Beecham Biolog Adjuvantien enthaltende Impfstoffzusammensetzung
ATE204762T1 (de) 1993-03-23 2001-09-15 Smithkline Beecham Biolog 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
PL181241B1 (pl) 1993-11-17 2001-06-29 Deutsche Om Arzneimittel Gmbh Disacharydy beta(1 6)glukozoaminowe, sposób wytwarzania disacharydu beta(1 6) glukozoaminowego, zawierająca je kompozycja farmaceutyczna i środek immunomodulujący i/lub przeciwnowotworowy oraz szczepionka
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
CA2194761C (en) 1994-07-15 2006-12-19 Arthur M. Krieg Immunomodulatory oligonucleotides
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
GB9620795D0 (en) 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
DE69733020T2 (de) 1996-10-11 2006-02-16 The Regents Of The University Of California, Oakland Immunostimulierende oligonucleotidekonjugate
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
ATE435661T1 (de) 1997-08-29 2009-07-15 Antigenics Inc Adjuvant qs-21 enthaltende zusammensetzungen mit polysorbate oder cyclodextrin als hilfsmittel
WO1999011241A1 (en) 1997-09-05 1999-03-11 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
AU2003299527A1 (en) * 2002-06-17 2004-06-07 Jimmy D. Ballard Mutant of clostridium difficile toxin b and methods of use
ATE544354T1 (de) * 2002-11-26 2012-02-15 Univ Chicago Vermeidung und behandlung von mikrobenübertragenen epithelerkrankungen
US7993864B2 (en) 2002-12-03 2011-08-09 Ucb Pharma S.A. Assay for identifying antibody producing cells
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
CA2527020A1 (en) 2003-07-01 2005-01-13 Celltech R & D Limited Modified antibody fab fragments
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
PT2270045E (pt) * 2004-02-06 2015-04-08 Univ Massachusetts Anticorpos contra toxinas de clostridium difficile e utilizações dos mesmos
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
CA2592015A1 (en) * 2004-12-27 2006-07-06 Progenics Pharmaceuticals (Nevada), Inc. Orally deliverable and anti-toxin antibodies and methods for making and using them
CA2592639C (en) 2004-12-27 2013-07-30 Andrew F. Kirby Reduced foam dispersions and formulations therefor
US8852600B2 (en) * 2006-06-08 2014-10-07 The Rockefeller University Codon-optimized DNA molecules encoding the receptor binding domains of Clostridium difficile toxins A and B, and methods of use thereof
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
CN104004088B (zh) * 2007-09-26 2017-11-07 Ucb医药有限公司 双特异性抗体融合物
CN101980723A (zh) * 2008-02-28 2011-02-23 3M创新有限公司 艰难梭菌芽孢的抗体及其用途
KR102095257B1 (ko) * 2008-06-25 2020-04-01 노바르티스 아게 Ｖｅｇｆ를 억제하는 안정하고 가용성인 항체
CN102164965B (zh) 2008-09-26 2016-03-30 Ucb医药有限公司 生物产品
AU2010215275B2 (en) * 2009-02-20 2016-03-31 Micropharm Limited Antibodies to Clostridium difficile toxins
EP2558493B1 (en) * 2010-04-15 2019-09-18 Progenics Pharmaceuticals, Inc. Antibodies for the treatment of clostridium difficile-associated infection and disease
WO2012055030A1 (en) * 2010-10-25 2012-05-03 National Research Council Of Canada Clostridium difficile-specific antibodies and uses thereof
US9815889B2 (en) * 2011-08-02 2017-11-14 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Antibodies for prevention and treatment of diseases caused by clostridium difficile
KR20140063825A (ko) * 2011-09-16 2014-05-27 유씨비 파마, 에스.에이. 클로스트리듐 디피실의 주요 외독소 tcda 및 tcdb에 대한 중화 항체
UA112203C2 (uk) * 2011-11-11 2016-08-10 Юсб Фарма С.А. Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
WO2014061783A1 (ja) * 2012-10-19 2014-04-24 株式会社イーベック クロストリジウム・ディフィシルの毒素に特異的なヒト抗体もしくはその抗原結合性断片
GB201411320D0 (en) * 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
GB201411420D0 (en) * 2014-06-26 2014-08-13 Ucb Biopharma Sprl Antibody constructs
US9107906B1 (en) * 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency

Also Published As

Publication number Publication date
MX2014002769A (es) 2014-06-11
SG11201400193SA (en) 2014-05-29
EA032475B1 (ru) 2019-06-28
JP6603685B2 (ja) 2019-11-06
HK1199463A1 (en) 2015-07-03
HRP20190917T1 (hr) 2019-07-26
PT2758432T (pt) 2019-06-14
HUE043661T2 (hu) 2019-08-28
CY1121673T1 (el) 2020-07-31
WO2013038156A1 (en) 2013-03-21
US20140348844A1 (en) 2014-11-27
JP2017149773A (ja) 2017-08-31
EP3617227A3 (en) 2020-06-03
LT2758432T (lt) 2019-06-10
TN2014000101A1 (en) 2015-07-01
DK2758432T3 (da) 2019-06-03
IL231167A0 (en) 2014-04-30
BR112014006175B1 (pt) 2020-02-11
CL2014000491A1 (es) 2014-12-26
EP3617227A2 (en) 2020-03-04
JP2020037555A (ja) 2020-03-12
EP2758432A1 (en) 2014-07-30
JP2015501286A (ja) 2015-01-15
ECSP14013316A (es) 2014-08-29
ES2729278T3 (es) 2019-10-31
CA2848611A1 (en) 2013-03-21
AU2012307157A1 (en) 2014-04-24
EP2758432B1 (en) 2019-03-06
BR112014006175A2 (pt) 2017-04-04
JP6152107B2 (ja) 2017-06-21
PL2758432T3 (pl) 2019-08-30
CO6930310A2 (es) 2014-04-28
CN103958544B (zh) 2018-04-24
AU2012307157B2 (en) 2017-08-03
CN103958544A (zh) 2014-07-30
ZA201402760B (en) 2016-03-30
SG10201701055WA (en) 2017-03-30
EA201400345A1 (ru) 2014-09-30
CN108424449A (zh) 2018-08-21
US10752676B2 (en) 2020-08-25
NZ623293A (en) 2016-05-27
KR20140063825A (ko) 2014-05-27
PE20141547A1 (es) 2014-10-25
US20200377578A1 (en) 2020-12-03

Similar Documents

Publication Publication Date Title
HK1199463A1 (en) Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile tcda tcdb
HK1210494A1 (zh) 用於細胞培養的裝置和方法
HK1199905A1 (en) Culturing of mesenchymal stem cells
IL236672B (en) System and methods for preparing vegetable cells from animal fats
HK1199886A1 (en) Clostridium difficile antibodies
EP2900808A4 (en) METHOD FOR DIFFERENTIATING STEM CELLS IN CHONDROCYTES
HRP20190018T1 (hr) Postupci i sustavi za saharizaciju biomase
HK1216999A1 (zh) 針對艱難梭菌的抗體
EP2776829A4 (en) METHODS AND USES OF METABOLIC PROFILING FOR DIFFICULT CLOSTRIDIUM INFECTION (CDI)
ZA201504388B (en) Method for culturing pluripotent stem cells
EP2714923A4 (en) METHOD AND COMPOSITIONS FOR DETECTING FUNCTIONAL CLOSTRIDIUM DIFFICILE TOXINS
EP2780351A4 (en) LIPOTHEICHOIC ACID OF DIFFICULT CLOSTRIDIUM AND USES THEREOF
AP2014007559A0 (en) Neutralising antibodies to the major exotoxins TCDA and TCDB of clostridium difficile
IL231661A0 (en) Clostridium difficile antibodies
GB201103718D0 (en) Isolation of cells